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ABSTRACT
Background: Cutaneous dermatoses and
malignancies have occurred at the sites of
vaccines.
Purpose: To describe a man who developed a
lichenoid dermatitis at the pneumococcal
vaccine injection site and to review cutaneous
dermatoses and malignancies occurring at
vaccination sites.
Methods: PubMed was used to search the
following terms, separately and in
combination: adverse, condition, cutaneous,
dermatosis, dermatitis, injection, PCV13,
pneumococcal, pneumonia, prevnar, reaction,
skin, site, vaccination, and vaccine. All papers
were reviewed, and relevant manuscripts, along
with their reference citations, were evaluated.
Results: Several vaccines—including bacillus
Calmette-Guerin, hepatitis B, influenza,
leishmaniasis, meningitis, pneumococcal,
smallpox, tetanus (alone and in combination
with diphtheria, pertussis, polio, Haemophilus
influenza type B or plague and yellow fever),
and varicella-zoster—have been associated with
post-vaccination site reactions. A 70-year-old
male developed a lichenoid dermatitis that
occurred at the pneumococcal vaccine injection
site within 2 weeks after PCV13 vaccination; the
erythematous nodule resolved spontaneously
within 9 weeks following immunization.
Conclusions: Dermatoses at the injection sites of
vaccines can be granulomatous, immunity-related
conditions, infections, lichenoid, neutrophilic, or
pseudolymphomatous. Basal cell carcinoma and
squamous cell carcinoma are the most common
vaccination site-associated malignancies;
however, melanoma and sarcomas
(dermatofibrosarcoma protuberans, fibrosarcoma,
and malignant fibrous histiocytoma) are also
smallpox vaccine-related site neoplasms. A
cutaneous immunocompromised district that is
created by vaccine-induced local immunologic
changes is hypothesized to be the pathogenesis of
vaccination site reactions.
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INTRODUCTION
The pneumococcal polysaccharide conjugated
vaccine (13-valent, adsorbed; PCV13, Prevnar
13) is approved in adults C50 years for the
prevention of pneumonia in the USA [1–3].
Lichenoid dermatitis describes a skin condition
that is microscopically characterized by
band-like lymphocytic inflammation with
alteration of the epidermal basal layer. The
case of a man who developed a lichenoid
dermatitis at the site of immunization within
2 weeks after receiving the PCV13 vaccine is
described, and cutaneous conditions occurring
at vaccinations sites are reviewed.
CASE REPORT
A 70-year-old male presented for evaluation of a
new, asymptomatic, red and scaly lesion on his
left arm. He had received a vaccination,
pneumococcal polysaccharide conjugated
vaccine (13-valent, adsorbed; PCV13, Prevnar
13) at the site 5 weeks earlier. Within 2 weeks
after being immunized, he noticed the skin
lesion. He had been vaccinated with the
pneumococcal polysaccharide vaccine
(PPSV23, Pneumovax) 6 years earlier.
Cutaneous examination showed a
12 9 5-mm linear, focally crusted,
erythematous nodule on the deltoid area of his
left arm (Fig. 1); the location corresponded to
the PCV13 injection site.
Microscopic evaluation of a 3-mm punch
biopsy showed orthokeratosis, acanthosis, and a
prominent granular layer. Dyskeratotic
keratinocytes were present in the epidermis,
and there was a vacuolar change of the basal
cells at the dermoepidermal interface. In the
upper dermis there was dense, band-like
infiltration of lymphocytes with occasional
exocytosis of the inflammatory cells into the
overlying spongiotic epidermis (Fig. 2).
Correlation of the history, clinical
morphology, and pathologic changes
established the diagnosis of a lichenoid
dermatitis occurring at the vaccination site of
the PCV13 vaccine. The residual dermatosis
resolved spontaneously within 4 weeks after the
biopsy, corresponding to 9 weeks after
immunization. Follow-up examination showed
normal-appearing skin at the vaccination site.
Fig. 1 Distant (a) and closer (b) views of the pneumococcal
vaccination site on the left deltoid area show a 129 5 mm
linear, focally crusted, erythematous nodule
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Informed consent was obtained from the
patient for being included in the study.
DISCUSSION
The 7-valent pneumococcal conjugated vaccine
(PCV, known by the trade name Prevnar) was
licensed by the Food and Drug Administration
(FDA) on 17 February 2000 [4]. Subsequently,
vaccines toward 13 and 23 serotypes of
Streptococcus pneumonia were developed. PCV13
consists of 13 serotype-specific polysaccharides
of S. pneumoniae (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C,
19A, 19F, and 23F) conjugated individually to
non-toxic diphtheria CRD197 carrier protein and
adsorbed on aluminum phosphate. The US
Advisory Committee on Immunization
Practices (ACIP) has recommended PCV13 [in
series with 23-valent pneumococcal
polysaccharide vaccine (PPVS23, Pneumovax)]
for all adults aged C65 years. A single 0.5-mm
dose is given as an intramuscular injection in
the deltoid muscle [3, 5–9].
PCV13 has been associated with not only
systemic adverse events, but also local reactions
of only mild or moderate severity; no
vaccine-related serious events were reported
[8]. Systemic adverse events associated with
the vaccine include arm movement limitation,
arthralgia, chills, decreased appetite, diarrhea,
fatigue, fever, headache, myalgia, rash, and
vomiting. In general, these reactions were less
common in older persons than in younger
individuals [1–3, 7].
Skin and subcutaneous tissue disorders
accounted for 20% of total adverse events
following immunization in a 10-year
retrospective analysis of spontaneous reports
following pediatric immunizations [10].
Cutaneous reactions to vaccinations can be
nonspecific or related to the live attenuated
virus; they can also be localized to the injection
site or associated with generalized
hypersensitivity reactions [11]. Investigators
have proposed not only the case definition,
but also the guidelines for collection, analysis,
and presentation of immunization safety data
for local reactions at or near vaccine injection
sites [12].
Fig. 2 Distant (a) and closer (b, c) views of the skin
biopsy show orthokeratosis, acanthosis, and a prominent
granular layer (a, b). There is mild spongiosis (c),
dyskeratotic keratinocytes (a, b), and vacuolar change of
the basal cells at the dermoepidermal interface (a–c).
Lymphocytes are present in a dense, band-like inﬁltrate in
the upper dermis (a, b), and there is exocytosis of the
inﬂammatory cells into the overlying epidermis (a,
c) (hematoxylin and eosin, a = 910; b = 920; c = 920)
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Cutaneous reactions at the site of PCV13 are
summarized in Table 1 [1–4, 13–17]. Local
reactions such as erythema, pain and swelling
at the injection site were common; they were
more severe in younger aged patients than in
older individuals [1–3]. The reported patient is
the first individual with a lichenoid dermatitis
that appeared at the vaccine injection site
within 2 weeks and spontaneously resolved in
9 weeks.
Cutaneous dermatoses and malignancies
have occurred at the sites of other vaccines,
including Bacillus Calmette-Guerin (Table 2)
[18–44], hepatitis B (Table 3) [28, 45–53],
smallpox (Table 4) [28, 54–79], tetanus (Table 5)
[14, 80–86], and others (Table 6) [36, 51, 55, 73,
87–97]. Granuloma annulare is one of the more
common skin conditions to subsequently occur
Table 1 Pneumococcal vaccination site reactions
Injection site reactions:
Abscess or cellulitisa [4]
Erythema, pain, and swellinga [1–4]
Itching granulomab [14]
Keratoacanthoma [15]
Lichenoid dermatitis [current report]
Sweet’s syndromec [16]
Delayed maturation of the antibody response to the
pneumococcal vaccine was observed in children with
atopic eczema who received Pneumovax II (Pasteur
Merieux MSD Ltd., Maidenhead, UK). Speciﬁcally, in
comparison to controls (of whom 57% responded to the
vaccine), only 17% of children with atopic dermatitis aged
3–8 years responded to Pneumovax II [13]
a Injection site reactions following vaccination with the
7-valent pneumococcal conjugated vaccine (PCV, trade
name Prevnar, Wyeth Pharmaceuticals, Philadelphia, PA)
were described in 54% of 4154 reports of events after
immunization; 8 serious reports described abscess or
cellulitis [4]
b Itching granuloma occurred in 38 of 4758 children
(0.83%) who received Infanrix or Pentavac alone or
concomitant with pneumococcal conjugate (Prevnar).
Accompanying clinical features at the injection site in
some of the patients also included bluish discoloration,
dermatitis, excoriations, hyperpigmentation,
hypertrichosis, and scar. Contact allergy to aluminum
was veriﬁed in 29 of the 34 children (85%) who were
evaluated by epicutaneous testing with aluminum
c Sweet’s syndrome was also triggered by pneumococcal
vaccination that had taken place 15 days earlier; however,
the patient did not have any lesions at the injection site
[17]
Table 2 Bacillus Calmette-Guerin (BCG) vaccination site
reactions
Abscess [18–20]
Basal cell carcinoma [21]
Blistering [18, 19, 22]
Epithelial cysts [18, 19, 22]
Erythema [18, 19, 22]
Erythematous nodule (necrotizing granulomatous
reaction) [22]
Fixed drug eruption [23]
Foreign body granuloma (non-necrotizing) [24]
Granuloma annulare [25, 26]
Granuloma (delayed) [19]
Isotopic response to patch testing [27]
Keloid [7, 19, 22, 28]
Lupus vulgaris (cutaneous tuberculosis) [29–33]





Squamous cell carcinoma [33, 38]
Sweet’s syndrome [39, 40]
Tufted angioma [41]
Ulceration [18, 19, 22]
Ulceration during Kawasaki disease [42, 43]
Vasculitis (ulcerating) [44]
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at the site of an immunization [25, 26, 46, 98, 99].
The most frequently observed vaccination
site-associated malignancy is basal cell
carcinoma [33, 38, 55–57, 73], followed by
squamous cell carcinoma [33, 38, 54, 55, 57,
73]. However, the prevalence of melanoma [55,
57, 73] and sarcomas (dermatofibrosarcoma
protuberans, fibrosarcoma, and malignant
fibrous histiocytoma) [55, 57, 60–62, 72] in
smallpox vaccination scars—as compared to the
scars of other vaccines—is greater than expected
and may be secondary to a unique characteristic
of the vaccine (Table 7) [15, 33, 38, 54–57, 60–62,
69, 72, 73, 86, 90, 94–96].
Vaccine-associated adverse effects at the site
of injection may, in part, be secondary to the the
polysaccharides and bases it contains. However,
there are no predictors as to which individuals
will develop these side effects. It remains to be
determined why some patients experienced
inflammatory dermatoses whereas others
developed neoplasms at their vaccination sites.
Table 3 Hepatitis B vaccination site reactions
Churg–Strauss vasculitis [45]
Granuloma annulare [46]






Papulonodular lichenoida and pseudolymphomatous
reaction [47]
Subcutaneous nodule (cutaneous B-cell
pseudolymphoma) [51]
a Generalized lichenoid reactions and lichen planus have
occurred following hepatitis B vaccination; however, the
initial or individual lesion was not localized to the site of
vaccination [52, 53]
Table 4 Smallpox vaccination site reactions
Allergic contact dermatitis [54]
Basal cell carcinoma [55–57]
Dermatitis, chronic [54]
Dermatoﬁbroma [58, 59]
Dermatoﬁbrosarcoma protuberans [55, 57, 60, 61]
Fibrosarcoma [62]
Herpes simplex virus infection [63]
Inﬂammatory reaction, localizeda [64]
Keloid (exaggerated scarring) [28, 55, 64–68]
Keratoacanthoma [69]
Lupus erythematosus (discoid) [70, 71]
Malignant ﬁbrohistiocytoma [55, 57, 72]
Melanoma [55, 57, 73]
Myxedematous inﬁltration, diffuse (Graves’ disease) [74]
Nevus sebaceous [75]
Pigmentation [76, 77]




Scar response (normal)e [57, 78]
Squamous cell carcinoma [54, 55, 57]
Sweet’s syndrome [79]
a A localized inﬂammatory reaction at the vaccination site
heals with a slightly depressed smooth scar that slowly fades
and rarely requires treatment
b The morphology of the lesion includes (in order of
frequency) erythema, papule, pustule, vesicle, induration, and
scab; all except induration and scab may recur in some
patients after the original lesions spontaneously resolve. Lesion
biopsies (in 4 patients) showed allergic contact dermatitis (2),
chronic dermatitis (1), and squamous cell carcinoma (1)
c Progressive vaccinia is also referred to as disseminated
vaccinia, prolonged vaccinia, vaccinia gangrenosum, and
vaccinia necrosum. The vaccination site does not heal; there
is painless progressive necrosis that develops into an ulcerative
lesion. Additional lesions may or may not appear at distant
sites, such as skin, bone, and viscera
d Robust take is a non-progressive cutaneous reaction at the
vaccination site of[7.5 cm with swelling, warmth, and joint
pain; the symptoms peak at 8–10 days post vaccination, and
there is improvement within 24–72 h
e The normal scar response at the site of vaccination is the
following sequence: papule at day 4 post vaccination, pustule
at day 7–14, and scab at day 21
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Ruocco et al. proposed the
immunocompromised district as a unifying
concept for the development of skin disorders
and cancer at lymphoedematous,
herpes-infected, and otherwise damaged
cutaneous sites in 2009 [99]. The concept has
subsequently been expanded with regards to
not only the factors responsible for the regional
immune dysregulation (which also include
burns, ionizing and ultraviolet radiation,
neurologic disorders such as paralytic stroke
and poliomyelitis, tattooing, and trauma such
as amputation), but also the skin diseases
arising in the affected sites (such as
granulomatous reactions, immunity-related
disorders, infections, and tumors) [100–102].
The occurrence of cutaneous dermatoses or skin
cancers at vaccination sites is another example
of an immunocompromised cutaneous district
that has been created by local immunologic
changes induced by the vaccine.
Table 5 Tetanus vaccination site reactions
Tetanus vaccine
Angiolymphoid hyperplasia with eosinophils [80]
Indurated erythematous plaque (cutaneous B-cell
pseudolymphoma) [51]
Granuloma annulare [81]
Tetanus and diphtheria vaccine
Granuloma annulare [26]
Tetanus, diphtheria, and pertussis vaccine
Abscess (Mycobacterium tuberculosis) [82]
Deep reactive nodular inﬁltrates of mixed
inﬂammation [83]
Necrotizing granuloma [83]
Tetanus, diphtheria, pertussis, and polio vaccine
Abscess (Mycobacterium chelonei) [84]
Tetanus, diphtheria, pertussis, polio, and Haemophilus
inﬂuenza type B vaccine
Itching granulomaa [14]
Subcutaneous nodule (sterile abscess)b [85]
Tetanus, plague, and yellow fever vaccine
Dermatoﬁbrosarcoma protuberans [86]
a Itching granuloma occurred in 38 of 4758 children
(0.83%) who received Infanrix or Pentavac alone or
concomitant with pneumococcal conjugate (Prevnar).
Accompanying clinical features at the injection site in
some of the patients also included bluish discoloration,
dermatitis, excoriations, hyperpigmentation,
hypertrichosis, and scar. Contact allergy to aluminum
was veriﬁed in 29 of the 34 children (85%) who were
evaluated by epicutaneous testing with aluminum
b The patient received the Pentacel vaccine
Table 6 Other vaccination site reactions
Early summer meningitis











Subcutaneous nodule (pseudolymphoma) [92]
Zosteriform eruption [93]
Vaccine not speciﬁed
Basal cell carcinoma [55, 73]
Dermatoﬁbrosarcoma protuberansa [55, 94, 95]
Lentigo maligna [96]
Lichen sclerosus et atrophicus [97]
Melanoma [55]
Squamous cell carcinoma [55, 73]
a Includes pigmented dermatoﬁbrosarcoma also referred
to as Bednar tumor [55, 94]
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CONCLUSION
Vaccination site reactions have been observed
following immunization with several vaccines
including Bacillus Calmette-Guerin, hepatitis B,
influenza, leishmaniasis, meningitis,
pneumococcal, smallpox, tetanus (alone and in
combination with diphtheria, pertussis, polio,
Haemophilus influenza type B or plague and
yellow fever), and varicella-zoster. The reactions
at the vaccine injection sites are either cutaneous
dermatoses or neoplasms. In this report, a man is
described who developed a lichenoid dermatitis
that occurred at the pneumococcal vaccine
injection site within 2 weeks after PCV13
vaccination; the erythematous nodule resolved
spontaneously within 9 weeks following
immunization. Dermatoses at the injection sites




site-associated malignancies most commonly are
basal cell carcinoma or squamous cell carcinoma;
however, smallpox vaccine-related site neoplasms
also include melanoma and sarcomas
(dermatofibrosarcoma protuberans,
fibrosarcoma, and malignant fibrous
histiocytoma). The pathogenesis of vaccination
site reactions is hypothesized to be the result of a
cutaneous immunocompromised district created
by vaccine-induced local immunologic changes.
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Table 7 Cancers at vaccination sites
Basal cell carcinoma
Bacillus Calmette-Guerin vaccine [33, 38]
Smallpox vaccine [55–57]
Not speciﬁed [55, 72]
Dermatoﬁbrosarcoma protuberansa
Leishmaniasis immunization [90]
Smallpox vaccine [55, 57, 60, 61]
Tetanus, plague, and yellow fever vaccines [86]
Travel immunization [94]
Not speciﬁed [55, 95]
Fibrosarcoma





Smallpox vaccine [55, 57, 72]
Melanoma
Smallpox vaccine [55, 57, 73]
Not speciﬁed [55, 96]
Squamous cell carcinoma
Bacillus Calmette-Guerin vaccine [33, 38]
Smallpox vaccine [54, 55, 57]
Not speciﬁed [55, 73]
a These also include pigmented dermatoﬁbrosarcoma
protuberans (Bednar tumors) [55, 94]
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